Literature DB >> 22266849

DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

A Mitra1, M E Menezes, L K Pannell, M S Mulekar, R E Honkanen, L A Shevde, R S Samant.   

Abstract

Elevated levels of the oncoprotein, osteopontin (OPN), are associated with poor outcome of several types of cancers including melanoma. We have previously reported an important involvement of DNAJB6, a member of heat-shock protein 40 (HSP40) family, in negatively impacting tumor growth. The current study was prompted by our observations reported here which revealed a reciprocal relationship between DNAJB6 and OPN in melanoma specimens. The 'J domain' is the most conserved domain of HSP40 family of proteins. Hence, we assessed the functional role of the J domain in activities of DNAJB6. We report that the J domain of DNAJB6 is involved in mediating OPN suppression. Deletion of the J domain renders DNAJB6 incapable of impeding malignancy and suppressing OPN. Our mechanistic investigations reveal that DNAJB6 binds HSPA8 (heat-shock cognate protein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3β (GSK3β) at Ser 9 by recruiting protein phosphatase, PP2A. This dephosphorylation activates GSK3β, leading to degradation of β-catenin and subsequent loss of TCF/LEF (T cell factor1/lymphoid enhancer factor1) activity. Deletion of the J domain abrogates assembly of this multiprotein complex and renders GSK3β inactive, thus, stabilizing β-catenin, a transcription co-activator for OPN expression. Our in-vitro and in-vivo functional analyses show that silencing OPN expression in the background of deletion of the J domain renders the resultant tumor cells less malignant despite the presence of stabilized β-catenin. Thus, we have uncovered a new mechanism for regulation of GSK3β activity leading to inhibition of Wnt/β-catenin signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266849      PMCID: PMC3717376          DOI: 10.1038/onc.2011.623

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

Review 1.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

2.  Osteopontin expression correlates with melanoma invasion.

Authors:  David Denhardt
Journal:  J Invest Dermatol       Date:  2005-05       Impact factor: 8.551

3.  DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype.

Authors:  Aparna Mitra; Mitchell E Menezes; Lalita A Shevde; Rajeev S Samant
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

Review 4.  The WNT/Beta-catenin pathway in melanoma.

Authors:  Lionel Larue; Véronique Delmas
Journal:  Front Biosci       Date:  2006-01-01

5.  Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation.

Authors:  Louise R Howe; Osamu Watanabe; James Leonard; Anthony M C Brown
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit.

Authors:  Kimberly Lin; Stavroula Baritaki; Loredana Militello; Graziella Malaponte; Ylenia Bevelacqua; Benjamin Bonavida
Journal:  Genes Cancer       Date:  2010-05

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

Review 8.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 9.  Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology.

Authors:  Franziska Buback; Andreas C Renkl; Guido Schulz; Johannes M Weiss
Journal:  Exp Dermatol       Date:  2009-06-23       Impact factor: 3.960

10.  Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Authors:  Aparna Mitra; Rebecca A Fillmore; Brandon J Metge; Mathur Rajesh; Yaguang Xi; Judy King; Jingfang Ju; Lewis Pannell; Lalita A Shevde; Rajeev S Samant
Journal:  Breast Cancer Res       Date:  2008-03-07       Impact factor: 6.466

View more
  25 in total

1.  Cellular stress stimulates nuclear localization signal (NLS) independent nuclear transport of MRJ.

Authors:  Joel F Andrews; Landon J Sykora; Tiasha Barik Letostak; Mitchell E Menezes; Aparna Mitra; Sailen Barik; Lalita A Shevde; Rajeev S Samant
Journal:  Exp Cell Res       Date:  2012-04-03       Impact factor: 3.905

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 3.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

4.  GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.

Authors:  Ting-Ting Du; Le Wang; Chun-Li Duan; Ling-Ling Lu; Jian-Liang Zhang; Ge Gao; Xiao-Bo Qiu; Xiao-Min Wang; Hui Yang
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

5.  DNAJB6 governs a novel regulatory loop determining Wnt/β-catenin signalling activity.

Authors:  Mitchell E Menezes; Aparna Mitra; Lalita A Shevde; Rajeev S Samant
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

Review 6.  Neuromuscular Diseases Due to Chaperone Mutations: A Review and Some New Results.

Authors:  Jaakko Sarparanta; Per Harald Jonson; Sabita Kawan; Bjarne Udd
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

7.  HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Authors:  C-H Chen; W-H Chang; K-Y Su; W-H Ku; G-C Chang; Q-S Hong; Y-J Hsiao; H-C Chen; H-Y Chen; R Wu; P-C Yang; J J W Chen; S-L Yu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

Review 8.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

9.  The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters.

Authors:  Joo Ae Kim; Youngmi Kim; Byoung-Mog Kwon; Dong Cho Han
Journal:  J Biol Chem       Date:  2013-08-27       Impact factor: 5.157

10.  DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1.

Authors:  Hye-Youn Kim; Young-Mi Kim; Suntaek Hong
Journal:  Cell Death Dis       Date:  2021-05-08       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.